SNG
vs
F
FTSE All Share Index
SNG
Over the past 12 months, SNG has outperformed FTSE All Share Index, delivering a return of -77% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
SNG vs FTSE All Share Index
Performance Gap
SNG vs FTSE All Share Index
Performance By Year
SNG vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Synairgen PLC
Glance View
Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The firm is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The firm is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The firm offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.